Table 1.

Discovery and validation cohort characteristics. Clinical characteristics for all individuals in the discovery and validation immunotherapy cohorts are shown. All patients (n = 33) were diagnosed with stage IV metastatic disease and were treated with immunotherapy agents. RNA-seq and whole exome sequencing (WES) was performed on n = 33 tumor samples prior to immunotherapy treatment. Patients from the discovery cohort belonged to the clinical trial published by Choueiri et al., 2016, while patients from the validation cohort belonged to multiple institutions.

Cohort	Sample Size	Site of Biopsy	Age	Sex		First-line treatment		Immunotherapy Treatment	Therapy Dose
				M	F	Y	N		0.3 mg/kg	2 mg/kg	10 mg/kg
Discovery	n = 16	Soft tissue metastases	62.88	n = 13	n = 3	n = 3	n = 13	Nivolumab n = 16	n = 4	n = 5	n = 10
Validation	n = 17	Multiple Locations	63.06	n = 11	n = 6	n = 7	n = 10	Nivolumab n = 11 Atezolizumab n = 2 Nivolumab + ipilimumab n = 4	Unknown